Competition from Constellation

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Competition from Constellation

posted on Dec 13, 2017 09:01AM

Looks like we now have another trial in the mCRPC arena. Constellation has talked about it for a while and now have dosed first patient in their Phase 1 program. Will be interesting to see how it does vs. ZEN3694. It seems Zenith is still ahead in this space, but others are jumping into the mix now.

https://www.businesswire.com/news/home/20171212005239/en/Constellation-Pharmaceuticals-Announces-Patient-Dosed-Phase-1b2